Biomarker Lens

Biomarkers · Chemical

Anti-Vedolizumab Antibody

Understand what Anti-Vedolizumab Antibody signals

Primary unit
ng/mL
LOINC codes
90794-9, 86899-2, 86898-4
Commercial laboratory assays
3

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Anti-Vedolizumab Antibody

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Vedolizumab and Anti-Vedolizumab Antibody, Dose ASSURE™ VDZ

Laboratory
Labcorp
Test code
504567
Specimen
Serum
Fasting
Not stated
LOINC
90794-9
Turnaround
8 - 15 days

Laboratory assay overview

Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making.

Labcorp test directory, test code 504567

Vedolizumab Anti-drug Antibody

Laboratory
Quest Diagnostics
Test code
18231
Specimen
Serum
Fasting
Not stated
LOINC
86899-2
Turnaround
Set up: Tues, Thurs, Sat

Laboratory assay overview

Vedolizumab is a therapeutic monoclonal antibody against an integrin associated with lymphocyte migration into the gastrointestinal tract. It is used to treat moderate to severe ulcerative colitis and Crohn's disease. It is not significantly immunogenic and only a small percentage of treated patients develop antibodies. However, in these patients, antibodies may be associated with lower trough levels of the drug. Results >15 ng/mL indicate the presence of anti-drug antibody.

View complete laboratory reference notes

<15 ng/mL

Quest Diagnostics test directory, test code 18231

Vedolizumab Level and Anti-drug Antibody

Laboratory
Quest Diagnostics
Test code
18220
Specimen
Serum
Fasting
Not stated
LOINC
86898-4, 86899-2

Laboratory assay overview

Vedolizumab is a therapeutic monoclonal antibody against an integrin associated with lymphocyte migration into the gastrointestinal tract. It is used to treat moderate to severe ulcerative colitis and Crohn's disease. It is not significantly immunogenic and only a small percentage of treated patients develop antibodies. However, in these patients, antibodies may be associated with lower trough levels of the drug. Results >15 ng/mL indicate the presence of anti-drug antibody.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Vedolizumab LevelSee Laboratory Report
Vedolizumab Ab<15 ng/mL
View complete laboratory reference notes

Vedolizumab Level | See Laboratory Report Vedolizumab Ab | <15 ng/mL

Quest Diagnostics test directory, test code 18220

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.